The PharmAla
Manufacturing · Canada · 11-50 Employees
View Company Info for Free
Overview
Headquarters
1 Adelaide St E Ste 801, Toronto, Ontari...Phone Number
(855) 444-6362Website
www.pharmala.caRevenue
<$5 MillionStock Symbol
MDMAIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About The PharmAla
PharmAla Biotech Holdings Inc. is a Canadian biotechnology company focused on the research, development, manufacturing, and supply of clinical-grade MDMA and related MDXX class molecules for use in regulated research and therapeutic settings. The company was founded with the goal of alleviating the global shortage of generic, clinical-grade MDMA to support clinical trials and develop novel compounds with improved safety profiles, using a regulatory-first approach that emphasizes compliance with health authorities. PharmAla works with established laboratories across Canada to produce its products under Good Manufacturing Practice (GMP) standards and is involved in preclinical research and partnerships aimed at expanding access to its therapies in select jurisdictions.Explore more
The PharmAla Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is The PharmAla your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
The PharmAla, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once The PharmAla has new funding data
Website visits: Recent activity has been detected on your website
Check if The PharmAla has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on The PharmAla recently announced quarterly report
Click to see if The PharmAla had a recent Job posting/layoffs
Check out if The PharmAla is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at The PharmAla
Product Launch: Get notified when The PharmAla launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to The PharmAla
Compare insights from companies similar to The PharmAla, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
The PharmAla is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
The PharmAla is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about The PharmAla.
The PharmAla Tech Stack
A closer look at the technologies used by The PharmAla
Most Recent Scoops
Partnership
The PharmAla has established partnerships to supply its MDMA products to patients, doctors, and institutions in multiple countries. The company is supplying to the U.S. Veterans Affairs Administration, U.S. military, major universities, and has signed distributors in New Zealand, the Netherlands, Switzerland, and the Czech Republic.
Healthcare Technology
Project
The PharmAla has developed multiple MDMA-based products: Linneo (generic MDMA), ALA-02 (a safer MDMA variant for social anxiety), and APA-01 (for neurological disorders). APA-01 is designed to regrow neuronal connections in damaged parts of the brain.
Product Development, Medical Research, Pharmaceuticals
Project
The PharmAla is the world's leading manufacturer and supplier of MDMA for clinical use, with a first-mover advantage in every market where it sells. The company is also developing patented novel chemical entities based on MDMA for various indications.
Product Development, Pharmaceuticals, Manufacturing Operations
Project
estimates the potential market for its PTSD treatment to be worth approximately $260 million to $1.5 billion, targeting a condition that affects soldiers, firefighters, policemen, doctors, and nurses, especially in the wake of the pandemic.
Product Development, Healthcare Technology
Project
Product Development, Medical Research, Pharmaceuticals
The PharmAla News & Media
Jupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotech
Transaction Positions JUNS at the Forefront of Next-Generation MDMA-Based Therapeutics Following President Trump's April 18, 2026, Executive Order Accelerating Psychedelic MedicinePharmAla Biotech Executes Definitive Agreement to Form Special Purpose Vehicle, Restora Neurosciences, for Clinical Development of Patented Novel MDXX Molecule APA-01
PharmAla announces signed definitive agreement to form a special purpose vehicle to spin out APA-01 entity for development, partnering with DitebaPharmAla Executes Binding Letter of Intent for Formation of Special Purpose Vehicle to Develop Patented Novel MDXX Molecule APA-01
PharmAla signs a binding letter of intent to spin out its APA-01 novel asset into a joint venture with Aluvaris and Diteba, with deal to close in June.PharmAla Issues Q2 Financial Statements and Grants Options
PharmAla files Q2 quarterly financials with increased customer deposits.
Read more news
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding The PharmAla
Sign Up For FreeTo access detailed company insights
PharmAla Biotech Holdings Inc. is a Canadian biotechnology company focused on the research, development, manufacturing, and supply of clinical-grade MDMA and related MDXX class molecules for use in regulated research and therapeutic settings. The company was founded with the goal of alleviating the global shortage of generic, clinical-grade MDMA to... Read More
